Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 2
2008 1
2009 2
2010 7
2011 2
2012 1
2013 4
2014 3
2015 5
2016 3
2017 3
2018 2
2019 6
2020 6
2021 10
2022 5
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
PAZEC: a Dutch Gynaecological Oncology Group open-label, multicenter, phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer.
Westermann A, Ottevanger P, Reyners A, Kroep JR, Van Oijen MGH, Lalisang R, Witteveen PO. Westermann A, et al. Among authors: witteveen po. Int J Gynecol Cancer. 2024 Jan 6:ijgc-2023-004781. doi: 10.1136/ijgc-2023-004781. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 38184318
WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.
Embaby A, Kutzera J, Geenen JJ, Pluim D, Hofland I, Sanders J, Lopez-Yurda M, Beijnen JH, Huitema ADR, Witteveen PO, Steeghs N, van Haaften G, van Vugt MATM, de Ridder J, Opdam FL. Embaby A, et al. Among authors: witteveen po. Gynecol Oncol. 2023 Jul;174:239-246. doi: 10.1016/j.ygyno.2023.05.063. Epub 2023 May 24. Gynecol Oncol. 2023. PMID: 37236033 Clinical Trial.
Frailty and checkpoint inhibitor toxicity in older patients with melanoma.
Bruijnen CP, Koldenhof JJ, Verheijden RJ, van den Bos F, Emmelot-Vonk MH, Witteveen PO, Suijkerbuijk KPM. Bruijnen CP, et al. Among authors: witteveen po. Cancer. 2022 Jul 15;128(14):2746-2752. doi: 10.1002/cncr.34230. Epub 2022 Apr 19. Cancer. 2022. PMID: 35439334 Free PMC article.
Distinct Genomic Profiles Are Associated with Treatment Response and Survival in Ovarian Cancer.
de Witte CJ, Kutzera J, van Hoeck A, Nguyen L, Boere IA, Jalving M, Ottevanger PB, van Schaik-van de Mheen C, Stevense M, Kloosterman WP, Zweemer RP, Cuppen E, Witteveen PO. de Witte CJ, et al. Among authors: witteveen po. Cancers (Basel). 2022 Mar 15;14(6):1511. doi: 10.3390/cancers14061511. Cancers (Basel). 2022. PMID: 35326660 Free PMC article.
Patient-Reported Outcomes During Checkpoint Inhibition: Insight into Symptom Burden in Daily Clinical Practice.
Koldenhof JJ, van der Baan FH, Verberne EG, Kamphuis AM, Verheijden RJ, Tonk EH, van Lindert AS, van der Stap J, Teunissen SC, Witteveen PO, Suijkerbuijk KP. Koldenhof JJ, et al. Among authors: witteveen po. J Pain Symptom Manage. 2022 Jun;63(6):997-1005. doi: 10.1016/j.jpainsymman.2022.02.013. Epub 2022 Feb 20. J Pain Symptom Manage. 2022. PMID: 35196557 Free article.
Functional decline after surgery in older patients with head and neck cancer.
Bruijnen CP, de Groot LGR, Vondeling AM, de Bree R, van den Bos F, Witteveen PO, Emmelot-Vonk MH. Bruijnen CP, et al. Among authors: witteveen po. Oral Oncol. 2021 Dec;123:105584. doi: 10.1016/j.oraloncology.2021.105584. Epub 2021 Oct 30. Oral Oncol. 2021. PMID: 34742007 Free article.
Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: An efficacy study.
van Triest B, Rasing M, van der Velden J, de Hullu J, Witteveen PO, Beukema JC, van der Steen-Banasik E, Westerveld H, Snyers A, Peters M, Creutzberg CL, Nout RA, Lutgens L, Jürgenliemk-Schulz I. van Triest B, et al. Among authors: witteveen po. Gynecol Oncol. 2021 Oct;163(1):117-124. doi: 10.1016/j.ygyno.2021.07.020. Epub 2021 Jul 21. Gynecol Oncol. 2021. PMID: 34301412 Free article. Clinical Trial.
Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer.
van Weelden WJ, Lalisang RI, Bulten J, Lindemann K, van Beekhuizen HJ, Trum H, Boll D, Werner HMJ, van Lonkhuijzen LRCW, Yigit R, Forsse D, Witteveen PO, Galaal K, van Ginkel A, Bignotti E, Weinberger V, Sweegers S, Kroep JR, Cabrera S, Snijders MPLM, Inda MA, Eriksson AGZ; European Network for Individualized Treatment in Endometrial Cancer; Krakstad C, Romano A, van de Stolpe A, Pijnenborg JMA. van Weelden WJ, et al. Among authors: witteveen po. Am J Obstet Gynecol. 2021 Oct;225(4):407.e1-407.e16. doi: 10.1016/j.ajog.2021.05.007. Epub 2021 May 19. Am J Obstet Gynecol. 2021. PMID: 34019887 Free article.
56 results